^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Source:
Title:

Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.

Published date:
05/16/2018
Excerpt:
There were three cases identified where HER2 mutation status impacted the selection of personalized anti-HER2 therapies….Case 1 was a HER2 positive patient with an ERBB2 mutation (c.1900T>C/p.C634R) who was resistant to trastuzumab and lapatinib but sensitive to afatinib.
DOI:
10.1200/JCO.2018.36.15_suppl.1039